Cargando…
Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice
Wilms tumor 1 (WT1) is a zinc finger transcriptional regulator, and has been implicated as both a tumor suppressor and oncogene in various malignancies. Mutations in the DNA-binding domain of the WT1 gene are described in 10–15% of normal-karyotype AML (NK-AML) in pediatric and adult patients. Simil...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219680/ https://www.ncbi.nlm.nih.gov/pubmed/30450160 http://dx.doi.org/10.18632/oncotarget.26238 |
_version_ | 1783368697723748352 |
---|---|
author | Annesley, Colleen E. Rabik, Cara Duffield, Amy S. Rau, Rachel E. Magoon, Daniel Li, Li Huff, Vicki Small, Donald Loeb, David M. Brown, Patrick |
author_facet | Annesley, Colleen E. Rabik, Cara Duffield, Amy S. Rau, Rachel E. Magoon, Daniel Li, Li Huff, Vicki Small, Donald Loeb, David M. Brown, Patrick |
author_sort | Annesley, Colleen E. |
collection | PubMed |
description | Wilms tumor 1 (WT1) is a zinc finger transcriptional regulator, and has been implicated as both a tumor suppressor and oncogene in various malignancies. Mutations in the DNA-binding domain of the WT1 gene are described in 10–15% of normal-karyotype AML (NK-AML) in pediatric and adult patients. Similar WT1 mutations have been reported in adult patients with myelodysplastic syndrome (MDS). WT1 mutations have been independently associated with treatment failure and poor prognosis in NK-AML. Internal tandem duplication (ITD) mutations of FMS-like tyrosine kinase 3 (FLT3) commonly co-occur with WT1-mutant AML, suggesting a cooperative role in leukemogenesis. The functional role of WT1 mutations in hematologic malignancies appears to be complex and is not yet fully elucidated. Here, we describe the hematologic phenotype of a knock-in mouse model of a Wt1 mutation (R394W), described in cases of human leukemia. We show that Wt1(+/R394W) mice develop MDS which becomes 100% penetrant in a transplant model, exhibit an aberrant expansion of myeloid progenitor cells, and demonstrate enhanced self-renewal of hematopoietic progenitor cells in vitro. We crossbred Wt1(+/R394W) mice with knock-in Flt3(+/ITD) mice, and show that mice with both mutations (Flt3(+/ITD)/Wt1(+/R394W)) develop a transplantable MDS/MPN, with more aggressive features compared to either single mutant mouse model. |
format | Online Article Text |
id | pubmed-6219680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-62196802018-11-16 Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice Annesley, Colleen E. Rabik, Cara Duffield, Amy S. Rau, Rachel E. Magoon, Daniel Li, Li Huff, Vicki Small, Donald Loeb, David M. Brown, Patrick Oncotarget Research Paper Wilms tumor 1 (WT1) is a zinc finger transcriptional regulator, and has been implicated as both a tumor suppressor and oncogene in various malignancies. Mutations in the DNA-binding domain of the WT1 gene are described in 10–15% of normal-karyotype AML (NK-AML) in pediatric and adult patients. Similar WT1 mutations have been reported in adult patients with myelodysplastic syndrome (MDS). WT1 mutations have been independently associated with treatment failure and poor prognosis in NK-AML. Internal tandem duplication (ITD) mutations of FMS-like tyrosine kinase 3 (FLT3) commonly co-occur with WT1-mutant AML, suggesting a cooperative role in leukemogenesis. The functional role of WT1 mutations in hematologic malignancies appears to be complex and is not yet fully elucidated. Here, we describe the hematologic phenotype of a knock-in mouse model of a Wt1 mutation (R394W), described in cases of human leukemia. We show that Wt1(+/R394W) mice develop MDS which becomes 100% penetrant in a transplant model, exhibit an aberrant expansion of myeloid progenitor cells, and demonstrate enhanced self-renewal of hematopoietic progenitor cells in vitro. We crossbred Wt1(+/R394W) mice with knock-in Flt3(+/ITD) mice, and show that mice with both mutations (Flt3(+/ITD)/Wt1(+/R394W)) develop a transplantable MDS/MPN, with more aggressive features compared to either single mutant mouse model. Impact Journals LLC 2018-10-19 /pmc/articles/PMC6219680/ /pubmed/30450160 http://dx.doi.org/10.18632/oncotarget.26238 Text en Copyright: © 2018 Annesley et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Annesley, Colleen E. Rabik, Cara Duffield, Amy S. Rau, Rachel E. Magoon, Daniel Li, Li Huff, Vicki Small, Donald Loeb, David M. Brown, Patrick Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice |
title | Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice |
title_full | Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice |
title_fullStr | Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice |
title_full_unstemmed | Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice |
title_short | Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice |
title_sort | knock-in of the wt1 r394w mutation causes mds and cooperates with flt3/itd to drive aggressive myeloid neoplasms in mice |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219680/ https://www.ncbi.nlm.nih.gov/pubmed/30450160 http://dx.doi.org/10.18632/oncotarget.26238 |
work_keys_str_mv | AT annesleycolleene knockinofthewt1r394wmutationcausesmdsandcooperateswithflt3itdtodriveaggressivemyeloidneoplasmsinmice AT rabikcara knockinofthewt1r394wmutationcausesmdsandcooperateswithflt3itdtodriveaggressivemyeloidneoplasmsinmice AT duffieldamys knockinofthewt1r394wmutationcausesmdsandcooperateswithflt3itdtodriveaggressivemyeloidneoplasmsinmice AT raurachele knockinofthewt1r394wmutationcausesmdsandcooperateswithflt3itdtodriveaggressivemyeloidneoplasmsinmice AT magoondaniel knockinofthewt1r394wmutationcausesmdsandcooperateswithflt3itdtodriveaggressivemyeloidneoplasmsinmice AT lili knockinofthewt1r394wmutationcausesmdsandcooperateswithflt3itdtodriveaggressivemyeloidneoplasmsinmice AT huffvicki knockinofthewt1r394wmutationcausesmdsandcooperateswithflt3itdtodriveaggressivemyeloidneoplasmsinmice AT smalldonald knockinofthewt1r394wmutationcausesmdsandcooperateswithflt3itdtodriveaggressivemyeloidneoplasmsinmice AT loebdavidm knockinofthewt1r394wmutationcausesmdsandcooperateswithflt3itdtodriveaggressivemyeloidneoplasmsinmice AT brownpatrick knockinofthewt1r394wmutationcausesmdsandcooperateswithflt3itdtodriveaggressivemyeloidneoplasmsinmice |